These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 8229153)

  • 1. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
    J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
    Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Brach del Prever A; Iantorno D; Forni C; Campanacci M
    Minerva Pediatr; 1995 Nov; 47(11):457-69. PubMed ID: 8684341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
    Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
    Dunst J; Jürgens H; Sauer R; Pape H; Paulussen M; Winkelmann W; Rübe C
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):919-30. PubMed ID: 7607966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.
    Donaldson SS; Torrey M; Link MP; Glicksman A; Gilula L; Laurie F; Manning J; Neff J; Reinus W; Thompson E; Shuster JJ
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):125-35. PubMed ID: 9747829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of non-metastatic Ewing's sarcoma (pelvis excluded). Results obtained in 48 cases combining local therapy (radiation and/or surgical) and adjuvant chemotherapy with vincristine, adriamycin, dactinomycin and cyclophosphamide].
    Sudanese A; Avella M; Toni A; Boriani S; Baldini N; Monesi M; Battistini A; Mancini A; Campanacci M
    Minerva Med; 1987 Apr; 78(7):473-82. PubMed ID: 3574734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
    Paulussen M; Ahrens S; Dunst J; Winkelmann W; Exner GU; Kotz R; Amann G; Dockhorn-Dworniczak B; Harms D; Müller-Weihrich S; Welte K; Kornhuber B; Janka-Schaub G; Göbel U; Treuner J; Voûte PA; Zoubek A; Gadner H; Jürgens H
    J Clin Oncol; 2001 Mar; 19(6):1818-29. PubMed ID: 11251014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
    Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
    J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
    Bacci G; Ferrari S; Bertoni F; Donati D; Bacchini P; Longhi A; Brach Del Prever A; Forni C; Rimondini S
    J Clin Oncol; 2000 Feb; 18(4):885-92. PubMed ID: 10673532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
    Ataergin S; Ozet A; Solchaga L; Turan M; Beyzadeoglu M; Oysul K; Arpaci F; Komurcu S; Surenkok S; Ozturk M
    Med Oncol; 2009; 26(3):276-86. PubMed ID: 18989798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
    Bacci G; Picci P; Mercuri M; Ferrari S; Longhi A; Cesari M; Rosito P; Mancini AF; Barbieri E; Baldini N
    Acta Oncol; 1998; 37(7-8):671-6. PubMed ID: 10050985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
    Deméocq F; Oberlin O; Benz-Lemoine E; Boilletot A; Gentet JC; Zucker JM; Behar C; Poutard P; Olive D; Brunat-Mentigny M
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S45-7. PubMed ID: 2667789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
    Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Iantorno D; Brach Del Prever A; Ruggieri P; Forni C
    Minerva Chir; 1997 Apr; 52(4):415-26. PubMed ID: 9265127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.